SCHEDULE: Glenview Capital Management Reports 0% Stake in Myriad Genetics

Glenview Capital Management and Larry Robbins have filed an amended Schedule 13G, reporting no beneficial ownership of Myriad Genetics Inc. common stock as of June 30, 2026.

Summary

• This filing is an amendment to a Schedule 13G, indicating a change in beneficial ownership reporting for Myriad Genetics Inc. common stock.
• Glenview Capital Management, LLC, along with its Chief Investment Officer Larry Robbins, are the reporting persons.
• The filing states that as of June 30, 2026, neither reporting person beneficially owns any shares of Myriad Genetics Inc. common stock.
• This means their aggregate beneficial ownership is 0 shares, representing 0% of the class.
• The filing also includes a joint filing agreement and a power of attorney for Larry Robbins appointing Mark J. Horowitz as his attorney-in-fact.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a neutral filing, primarily an administrative update regarding beneficial ownership, with no new financial or strategic information.

Negatives

• The reporting persons have zero beneficial ownership of Myriad Genetics Inc. common stock as of the filing date.

Future Outlook

No forward-looking statements or guidance are provided in this filing.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are typically used by institutional investors to report passive ownership stakes. A filing indicating zero ownership suggests a complete divestment or a lack of any current investment in Myriad Genetics Inc. by Glenview Capital Management.

Key Dates

Keywords

Schedule 13G, Beneficial Ownership, Glenview Capital Management, Myriad Genetics, SEC Filing, Amendment